<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827875</url>
  </required_header>
  <id_info>
    <org_study_id>AIV001-W02</org_study_id>
    <nct_id>NCT04827875</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy</brief_title>
  <official_title>An Exploratory Study to Evaluate the Safety and Efficacy of Intradermal Administration of AIV001 Aqueous Suspension on Scar Formation and Keloid Recurrence Following Keloidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AiViva BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AiViva BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate how safe and effective AIV001 treatment is on scar formation and/or keloid&#xD;
      recurrence following keloidectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Approximately 365 days</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Keloid recurrence</measure>
    <time_frame>365 days</time_frame>
    <description>Number of subjects experiencing keloid recurrence within study duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>AIV001 Treatment Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV001 Treatment Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal, Dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIV001</intervention_name>
    <description>Intradermal</description>
    <arm_group_label>AIV001 Treatment Dose 1</arm_group_label>
    <arm_group_label>AIV001 Treatment Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male of female, aged 18 to 60, inclusive&#xD;
&#xD;
          -  No clinically relevant abnormalities identified by a detailed medical history and&#xD;
             vital signs&#xD;
&#xD;
          -  Presence of one keloid scar, up to 2.2 cm length and up to 1.2 cm width, at least 1&#xD;
             year from formation, and located on trunk or arms&#xD;
&#xD;
          -  Willing to undergo surgical excision of keloid&#xD;
&#xD;
          -  No concurrent treatment of the study keloid or prior treatment within last 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior keloidectomy of study keloid&#xD;
&#xD;
          -  History of genetic disorder that predisposes to keloids (e.g., Ehlers-Danlos syndrome,&#xD;
             Ullrich congenital muscular dystrophy, etc.)&#xD;
&#xD;
          -  Corticosteroids (topical, injectable, inhalable, intranasal, or oral) within last two&#xD;
             months (except as prescribed by physician for seasonal allergies)&#xD;
&#xD;
          -  Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other&#xD;
             major systemic disease that could complicate execution of the protocol or&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and&#xD;
             fistula&#xD;
&#xD;
          -  Subject has active collagen vascular disease or vasculitis, e.g., systemic lupus&#xD;
             erythematosus, polyarthritis, dermatomyositis, systemic scleroderma or thrombotic&#xD;
             thrombocytopenic purpura&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scar formation</keyword>
  <keyword>Keloidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

